Skip to Main Content

Smilow and Yale Cancer Center Clinical and Research Town Hall | July 1, 2021

 .

Smilow and Yale Cancer Center Clinical and Research Town Hall | July 1, 2021

July 02, 2021

Hosted by Dr. Nita Ahuja

Presentation by: Drs. Marcus Bosenberg, Roy S. Herbst, Barbara Burtness, and Monica Fradkin, RN, MPH

ID
6771

Transcript

  • 00:00Alright, well good evening everybody.
  • 00:02Welcome to town Hall and just a
  • 00:05reminder before I get started.
  • 00:06You know, these are meant to engage in
  • 00:09and be a community of the wider community,
  • 00:12and we're about 2000 people.
  • 00:14If you think of the entire
  • 00:16community of the Yale Cancer Center,
  • 00:19the Smilow Cancer Hospital in
  • 00:21our ambulatory care sites, and I,
  • 00:23I hope that as these town halls
  • 00:25sort of continue to happen,
  • 00:27we start sharing and learning
  • 00:29about our neighbors.
  • 00:30Our metaphorical neighbors,
  • 00:31and learn about each other,
  • 00:33and perhaps then will lead to sort of
  • 00:35more enriched community and engagement.
  • 00:37So again,
  • 00:38just a reminder that sometimes it may
  • 00:41mean why are we doing all of this?
  • 00:43Because it is to sort of understand
  • 00:45all of all of the different parts,
  • 00:48and I'll briefly mention that this week,
  • 00:50Lori Pickens and I had the opportunity
  • 00:52to visit Torrington Care Center.
  • 00:54It was delightful to see all the the
  • 00:57busy space and all the the staff and
  • 00:59the physicians and the nursing teams.
  • 01:01So I think it is such a great
  • 01:04community we have.
  • 01:05We just need to acknowledge that better.
  • 01:07It's in our science whether it's our
  • 01:09trainees are nursing staff or care
  • 01:11centers in these sessions or these
  • 01:12these site time we spend together
  • 01:14we spend is to start to get to know
  • 01:16each other and then start to get
  • 01:18through a more richer space as a
  • 01:20result of that we have a lot of things,
  • 01:23but I do want to leave 10 to 15 to
  • 01:2520 minutes at the end for questions
  • 01:27I want to remind all of our speakers
  • 01:30to sort of respect that so we can then.
  • 01:33Really, our folks can ask questions,
  • 01:35and with that,
  • 01:36Renee if you want to move to the next slide.
  • 01:41Oh, I'm sorry I forgot one more thing.
  • 01:43Just a reminder.
  • 01:44We don't have town hall in August
  • 01:46because I do think everyone should
  • 01:49take vacation and often August
  • 01:50seems to be our favorite time of
  • 01:52the year to take vacation.
  • 01:54And we'll reconvene in September alright.
  • 01:56New appointments,
  • 01:57effective June 2021 these are.
  • 01:58This is why we are here.
  • 02:00You know this is the
  • 02:02test stuff you celebrate.
  • 02:03So it's really my pleasure to
  • 02:05announce our new Chief of Pediatric
  • 02:07Imunk and BMT service,
  • 02:08or bone marrow transplant service
  • 02:11Doctor Lakshman Krishnamurthi was
  • 02:13just appointed recently and he will
  • 02:15be starting with us on October
  • 02:171st 2021 Doctor this recruitment
  • 02:19was led by Doctor Cliff Bogart,
  • 02:22Chair of Pediatrics and Doctor
  • 02:24Krishnamoorthy is an accomplished
  • 02:25pediatric hematologist oncologist
  • 02:27and an international leader in
  • 02:29bone marrow transplant and the
  • 02:32treatment of hemoglobinopathies.
  • 02:33He's coming to us from Atlanta,
  • 02:36where he's professor of Pediatrics at
  • 02:39Emory University School of Medicine.
  • 02:41Director of the BMT program.
  • 02:43I think we also want to thank Doctor
  • 02:46Farzana push anchor who has been
  • 02:48interim chief of PT Monk and I think
  • 02:51I just learned this afternoon that
  • 02:53not only is Doctor Krishnamurthy
  • 02:55coming but his wife is joining us
  • 02:58in the Department of Pathology so we
  • 03:00really get our lucky and privileged that
  • 03:02we get two in one so they will both be
  • 03:06joining in the cancer space in October.
  • 03:08Next is Doctor John Visal Marske who has.
  • 03:11Been a long standing member of our community,
  • 03:14but it was recently appointed section Chief
  • 03:17of Endocrinology and Metabolism in the
  • 03:19Department of Internal Medicine following
  • 03:21a three year stint as our interim chief.
  • 03:24He is a member of our Yale Cancer
  • 03:26Center Signaling Network research
  • 03:28program and also clinically as the
  • 03:30part of our endocrinology program,
  • 03:32so really excited that John is taking
  • 03:35the leadership permanent leadership
  • 03:36and then many of you saw the recent
  • 03:39appointment of Doctor Barbara Burtness.
  • 03:41Who is Professor of medicine as the
  • 03:44interim associate Director for Diversity,
  • 03:45Equity and inclusion?
  • 03:46This is a new position and this is one
  • 03:49that many in the Community are broader.
  • 03:51Community felt strongly about
  • 03:53the entire past year.
  • 03:54There was a committee led by Harriet Cougar,
  • 03:56along with Kevin Billingsley
  • 03:58focused on that and they suggested
  • 04:00this and as a result of that,
  • 04:02we've had Doctor Burtness
  • 04:03appointed as an interim,
  • 04:05and you're going to hear
  • 04:06from Barbara later today.
  • 04:07So I don't want to give her Thunder away,
  • 04:10but you're going to see.
  • 04:12Why we all believed that she was the right
  • 04:15leader to help us launch this program?
  • 04:17But she has great leadership and
  • 04:19innovative ideas and how to create
  • 04:22a more inclusive workplace which
  • 04:23then leads to you know engagement
  • 04:25and why we all come to work.
  • 04:27So with that next slide.
  • 04:30OK,
  • 04:30more new appointments.
  • 04:31Doctor Marcus Bosenberg is also
  • 04:33a new announcement you saw,
  • 04:35and this is also he's the inaugural director
  • 04:37of the Yale Center for Immuno Oncology.
  • 04:40This is a bridge program which
  • 04:42is you know part of living in a
  • 04:44large robust universe as ours.
  • 04:46As we live in the hospital.
  • 04:48But we also live in the school and also
  • 04:51the university and this bridge program
  • 04:53links are a cancer menology program
  • 04:55with the Department of Immunobiology
  • 04:57and to take all the science the wonderful.
  • 05:00Clients and translate it so no one
  • 05:02could think of a better leader
  • 05:04than Marcus and Doctor Rosenberg's
  • 05:05research achievements and leader
  • 05:07Exploder ship experience will be
  • 05:09instrumental for taking us forward.
  • 05:11And Doctor Boesenberg is also giving
  • 05:13us a little bit of update on what he
  • 05:16hopes to accomplish under this new
  • 05:18program and then last but not least,
  • 05:21it's really my pleasure to announce the
  • 05:23appointment of Doctor Kim Blenman as
  • 05:25an assistant professor in in medicine,
  • 05:27also in medical oncology,
  • 05:28doctor Blenman will also have
  • 05:30a secondary appointment.
  • 05:31In the Department of Computer Science
  • 05:34at Yale School of Engineering and
  • 05:35Applied Sciences and her research
  • 05:37interests is reducing radiation in
  • 05:39therapy induced adverse reactions
  • 05:41at breast cancer.
  • 05:42So really, a wonderful set of
  • 05:44accomplishments and then more good news.
  • 05:46Next slide,
  • 05:47Renee.
  • 05:47This is really great news.
  • 05:49We had just had an 8.5 million grant from the
  • 05:52National Institute of General Medical
  • 05:55Sciences, which really answers some
  • 05:57other seeks to answer some of the big
  • 06:00questions of the so called natural.
  • 06:02Apple and this is really how sort of our
  • 06:05body takes all of the pieces and makes
  • 06:08them sort of work on a day to day basis.
  • 06:12In this grant will be is led by
  • 06:14Doctor Jason Crawford who's on the
  • 06:16West campus in the Yale Institute of
  • 06:18Biomolecular Design and Discovery.
  • 06:20And then he joined by people
  • 06:22in the Cancer Center,
  • 06:24including Doctor Noah Palm, Carol Dr,
  • 06:26Carolyn Johnson and Doctor Andrew Goodman,
  • 06:28who all had researched
  • 06:30backgrounds and chemical biology,
  • 06:31immunobiology and microbial pathogenesis so.
  • 06:33Really, a big news for us as a whole.
  • 06:36And then come next slide.
  • 06:38Continuing on the theme of good news,
  • 06:41Morgan live doctor Morgan Levine
  • 06:43just got the 2021 Vincent Christoph
  • 06:45Low Rising Star Award,
  • 06:47which is given by the American
  • 06:49Federation for Aging Research Doctors.
  • 06:51AVR Lord became the vice chair of
  • 06:53the NCCN colorectal cancer screening
  • 06:55guidelines panel Doctor Rachel Greenup
  • 06:57got the 2021 National Endowment
  • 06:59for Plastic Surgery grant from the
  • 07:02Plastic Surgery Foundation fund.
  • 07:03Her research on shared decision
  • 07:05making for breast reconstruction.
  • 07:07Working in partnership with our patients and
  • 07:10then Doctor Pam Kunz was appointed
  • 07:11as the Journal of Clinical Oncology
  • 07:13consultant editor for meeting proceedings,
  • 07:16which many of you may or may not know.
  • 07:19It's one of the big journals for oncology,
  • 07:21so really proud of all of our faculty
  • 07:24and their numerous achievements.
  • 07:27And just a reminder again for the
  • 07:29agenda today it's a packed agenda.
  • 07:31Kind of all the site first up
  • 07:33will be ambulatory care discovery
  • 07:35delivery by Monica Fradkin.
  • 07:36And then we'll go to the next
  • 07:38part with clinical CT updates,
  • 07:40which is a recurring features,
  • 07:42then that both the new leaders,
  • 07:43Barbara Burtness and Marcus
  • 07:45Bosenberg will talk
  • 07:46about their new rules. With that, I'm
  • 07:48going to turn it over to Monica
  • 07:50to talk to us about care delivery,
  • 07:52so take it away, Monica.
  • 07:55Thank you doctor Hooja.
  • 07:58Alright everyone, thank you for
  • 08:00allowing me to spend a few minutes of
  • 08:02time to share about the great work
  • 08:05that has been done around the care
  • 08:08delivery workflows and what I'd like
  • 08:10to do is just spend a few minutes to
  • 08:13talk about the high level work that
  • 08:15has been done under the Ambulatory
  • 08:18Transformation Committee for the Care
  • 08:20Delivery workflow team and really,
  • 08:22during this time I'm going to spend
  • 08:24a couple minutes to highlight
  • 08:26some of the assessments.
  • 08:27That have been done as
  • 08:29well as the deliverables,
  • 08:31the tools and techniques
  • 08:32that have been provided,
  • 08:33and where we are now.
  • 08:35So we will start with just a
  • 08:38review of the assessments on how
  • 08:40we got here and what we did is we
  • 08:44spent a tremendous amount of time.
  • 08:46Getting information not only from
  • 08:48patients but also from physicians,
  • 08:50staff from all areas,
  • 08:52all disease teams and locations across
  • 08:54the different delivery networks.
  • 08:56To understand how we were doing and
  • 08:59this was done at the you know last year.
  • 09:03But really what we found is that
  • 09:05there was a tremendous amount of
  • 09:08opportunity with the work that's being
  • 09:10done for improvement and so based
  • 09:13off of the hundreds of responses that we.
  • 09:16Received and many open comments,
  • 09:19there were six different teams that
  • 09:22really became that bubbled to the top
  • 09:25around clinic and infusion that we
  • 09:27had opportunities for improvement.
  • 09:30So just to give you an idea about the
  • 09:34broad span of the work that's being done,
  • 09:39there are six different
  • 09:41multidisciplinary teams.
  • 09:42There are 15 team leaders
  • 09:44that are supporting the.
  • 09:46Work of these six teams we have
  • 09:49more than 70 participants and
  • 09:51about 20 different providers.
  • 09:54Within all of these different teams.
  • 09:57The projects are in various stages.
  • 09:59There was no way to start
  • 10:01all of them at once,
  • 10:03so when we give this update
  • 10:05as I share this update,
  • 10:07there are some teams that have been
  • 10:09working for many months and there
  • 10:11are some that are just starting.
  • 10:13And really what happened is
  • 10:15part of this work.
  • 10:16Is there were additional assessments
  • 10:18and quality improvement methods that
  • 10:21we used to gather more information
  • 10:23to really dive into the work so
  • 10:25that we can optimize optimize
  • 10:26what is how we're doing.
  • 10:28Our work so each of the teams also
  • 10:32had deliverables and here is a
  • 10:34snapshot of the different deliverables
  • 10:36within the different teams.
  • 10:37But there was there's even more that
  • 10:40we could provide to information.
  • 10:42But for visit scheduling criteria was
  • 10:44created to determine what visit type
  • 10:46should be in person versus face to face,
  • 10:49face to face,
  • 10:50versus Tele health.
  • 10:51And we customized it based off
  • 10:54the treatment modality and that
  • 10:56team really created a lot of work.
  • 10:58And then we're going to take.
  • 11:00That information and use it within
  • 11:03the pre clinic prep work and post
  • 11:05clinic wrap up and the checkout
  • 11:08teams so that's so we can sustain
  • 11:11the different workflows that
  • 11:12patients have a meaningful visit
  • 11:14and that everyone is prepared
  • 11:17appropriately. We have optimization of
  • 11:20infusion flow and there were two areas
  • 11:22that really came to light was around the
  • 11:25pril at the pretreatment lab process,
  • 11:28as well as looking at advanced release
  • 11:31of orders when it's appropriate.
  • 11:33And in addition the work that's being
  • 11:36done around IQ and Lean TOS will also,
  • 11:39you know, was going to support
  • 11:41a lot of this infusion flow.
  • 11:45Enhancing the patient education experience
  • 11:47but also utilizing Tele visits or Tel
  • 11:49technology so that we can provide
  • 11:51education with patients and families,
  • 11:53but maybe not when they're directly
  • 11:55in the chair or in clinic,
  • 11:57but at home and then diagnostic,
  • 12:00imaging, optimization, and timeliness.
  • 12:01We know that there's a lot of
  • 12:04opportunity around understanding
  • 12:05capacity and utilization and how
  • 12:07that impacts our care on a regular
  • 12:09basis and then really understanding
  • 12:11what our volumes and what do we have.
  • 12:15Do we have what we need to meet the
  • 12:18demand and as well as there are there
  • 12:21patients that are going outside of our
  • 12:24our organization for these imaging tests?
  • 12:27So just going to share some example
  • 12:29of some different processes and
  • 12:31clinical tools that have been created
  • 12:33around the work that's being done.
  • 12:35So we looked at cause and effect diagrams
  • 12:38to really understand where where each of
  • 12:41the work and barriers may come into play.
  • 12:44We process mapped the different
  • 12:46workflows and this is an example
  • 12:48of something that was done for pre
  • 12:51clinic prep and visit criteria.
  • 12:53We looked at also assessment parameters,
  • 12:55so when we're looking at those process
  • 12:58mappings really understanding what
  • 13:00are the questions and the tools
  • 13:01that need to be used.
  • 13:03Because this can also be used
  • 13:05for the education when we go into
  • 13:08our pilot and training phases.
  • 13:10Utilizing epic tools that we really
  • 13:13didn't realize were available to us,
  • 13:15so using those tools to be more efficient
  • 13:19as well as examples of a new visit
  • 13:22type that was created to be able to
  • 13:25use for Tele visits for patient education.
  • 13:30And just some additional
  • 13:31education that has been provided.
  • 13:33And finally,
  • 13:34in order for us to do all this,
  • 13:37we need to be able to measure it and
  • 13:40understand what we're doing is effective.
  • 13:42And is it sustainable?
  • 13:44So we are with it when it within each
  • 13:47one of these groups we will have
  • 13:49metrics for each one of them that we
  • 13:52can that could be automated that were
  • 13:55standardized to the best possible and
  • 13:57that we can also measure pre and post.
  • 14:00Implementation of these pilots examples
  • 14:02is also to ensure that we measure
  • 14:05provider staff and patient satisfaction
  • 14:07using different surveys and looking at
  • 14:10productivity and performance measures.
  • 14:12So based off all that,
  • 14:14where are we now?
  • 14:16So just to give you a little
  • 14:19bit of an update,
  • 14:21the visit type scheduling criteria
  • 14:23and preclinic prep have combined
  • 14:25the work that has been done.
  • 14:27Now our assessments are completed.
  • 14:29Workflows and trainings have
  • 14:30been done and we're at the phase
  • 14:33of we're ready to pilot.
  • 14:34So we've identified those initial sites and
  • 14:37we have sites that are in the queue ready
  • 14:41once our first site is up and running,
  • 14:43the checkout team has three different
  • 14:45work groups made up. Of stakeholders,
  • 14:48workflows and epic optimizations,
  • 14:50and really what they've done is they've,
  • 14:53you know, used our resources of NCCN
  • 14:56using best practices that you know
  • 14:58the best practice committee to glean
  • 15:01information we they've created,
  • 15:03created a completed additional workflows and
  • 15:05surveys of not only physicians and providers,
  • 15:09but also the access staff so they can
  • 15:12really understand what's being done
  • 15:15where and and to understand that.
  • 15:17Workflows.
  • 15:18And using Epic in what I TS UM
  • 15:21solutions could be available,
  • 15:24so they're they're they're working
  • 15:26through that as well right now and
  • 15:29will really come up with some options.
  • 15:32Optimal workflows for this that is using
  • 15:35the disposition and the enhancing the
  • 15:38checkout process to ensure nothing gets
  • 15:41missed from a patient safety standpoint.
  • 15:43And then the video enabled patient education.
  • 15:46You know, tools are developed
  • 15:47in 3 pilots or in progress.
  • 15:50You can see that what's listed.
  • 15:52The infusion flow optimization is reviewing,
  • 15:55you know,
  • 15:56has been involved with the IQ lean
  • 15:59TOS initiative and other relatives.
  • 16:02They've also come.
  • 16:03Done some clinical optimal observations
  • 16:05for pre releasing the different
  • 16:07out for chemotherapy so we can
  • 16:10have a real good understanding of
  • 16:13current state and to understand
  • 16:15where the opportunities would be.
  • 16:17And finally diagnostic imaging
  • 16:18optimization is really around.
  • 16:20As I mentioned,
  • 16:21they're creating a dashboard for
  • 16:23utilization and capacity and
  • 16:25what will that will allow is
  • 16:27to understand where are where.
  • 16:29We have opportunities to fill slots more.
  • 16:32Or do we have?
  • 16:33And over capacity issue in one
  • 16:35location where we could maybe
  • 16:37shift some of the imaging tests to
  • 16:40other to other areas that are under
  • 16:43capacity and then really looking as I
  • 16:46mentioned earlier around the volumes.
  • 16:48And the location of the outmigration.
  • 16:51So in a real in short,
  • 16:53that is the care delivery.
  • 16:56Work group is a highly engaged team
  • 16:58of a lot of different people that
  • 17:01really want to take the opportunity
  • 17:04to improve workflow and processes.
  • 17:06And you know,
  • 17:07I am speaking on behalf of many and
  • 17:10that it really has been a great
  • 17:13way to bring teams together,
  • 17:16understand cross teams workflows
  • 17:17and identify best practices,
  • 17:19but also realize that.
  • 17:20We could do some things better and
  • 17:23utilizing the tools that are out
  • 17:24there and taking a fresh look so.
  • 17:28Thank
  • 17:29you Monica, UM, for that update.
  • 17:31I think I'd like to keep the questions
  • 17:33for for the end for the entire panel,
  • 17:36so will will ask the attendees to save
  • 17:38the questions and start typing them.
  • 17:40And then if you can answer them directly,
  • 17:43that's also OK. With that,
  • 17:44I'm going to turn it over to Doctor
  • 17:46Herbs and just a reminder just to
  • 17:49leave Question Time for Q and I'm
  • 17:51just going to remind everybody.
  • 17:53Keep keep the presentations brief
  • 17:54so we can leave more time for Q&A.
  • 17:57Doctor Herbs please.
  • 17:59Yeah thanks Nita, Uhm can you hear me?
  • 18:01We can thank you.
  • 18:03Yeah, I'm I'm here in Hartford with
  • 18:05the Hartford Care Center team or having
  • 18:08a celebration for Jonathan Sporn.
  • 18:09I'm sitting outside.
  • 18:10Hopefully it doesn't rain first.
  • 18:12I want to welcome Mary Ann Lessburg.
  • 18:15Today was her first day,
  • 18:16though it hardly seems like that
  • 18:18because Maryann has been engaged
  • 18:20ever since the minute we met her,
  • 18:23she'll be leading the breast
  • 18:24disease Center breast,
  • 18:25medical oncology and we're so
  • 18:27happy that you're on campus.
  • 18:29Today, Mary Ann sorry,
  • 18:30I didn't get to see you today
  • 18:32I'll find you tomorrow.
  • 18:33Uh, but uh, this is really a great recruit.
  • 18:35Mary Mary had comes to us from
  • 18:37Ohio State and, uh, well,
  • 18:38I hope you'll all get to meet
  • 18:40her very soon as we continue
  • 18:42to build our breast program.
  • 18:43Next slide, please.
  • 18:46So I'm here to talk about clinical
  • 18:48trials and give you a very brief update.
  • 18:51July 1st update next slide.
  • 18:56So I just wanted to just bring up why we
  • 18:58conduct clinical trials and this is taken
  • 19:01from the ICR website on some of these
  • 19:04images and some from the YCC website.
  • 19:06You know we're forced
  • 19:07collaborating very closely,
  • 19:08and you can see it's it's about education.
  • 19:11It's about science and research.
  • 19:13We want better treatments.
  • 19:14We want to bring medical
  • 19:16breakthroughs to the public.
  • 19:17It really is important to think about
  • 19:19clinical trials for the cutting edge,
  • 19:21best clinical care and also by
  • 19:23thinking about a clinical trial.
  • 19:25One has to think about the best standards of
  • 19:28care so it increases our quality of care.
  • 19:31And a reputation and the next slide.
  • 19:33You'll see this examples
  • 19:34of how it helps patients,
  • 19:36and several of these.
  • 19:37In fact, I think most of them
  • 19:39are Yale cancer patients who have
  • 19:41benefited from clinical trial.
  • 19:47Next bye. Safe and efficient trials network.
  • 19:52We're working on that we're offering.
  • 19:54Our systems were improving our standard
  • 19:56operating procedures when processes
  • 19:58that ensure increased investigator
  • 19:59responsibility and oversight,
  • 20:01we are now almost completely electronic.
  • 20:03That's been along coming,
  • 20:05but it's it's been great and we're recruiting
  • 20:08a there's a lot of recruiting going on.
  • 20:11I've interviewed someone today,
  • 20:13focus on education and training
  • 20:15of our staff at all levels.
  • 20:17We're gonna do some retraining.
  • 20:20Everyone needs to constantly be up on the
  • 20:23regulatory data and we want to focus on
  • 20:26activation of trials and closure of traps.
  • 20:28Cloudsat, arner,
  • 20:29crewing should be closed and
  • 20:31we need more trials obviously,
  • 20:33but selective activation.
  • 20:34The trials that will really accrue
  • 20:36across our network next slide.
  • 20:41So just a little bit of
  • 20:42good news, I got this.
  • 20:46Our activation team just about 2 hours ago.
  • 20:49There are 57 studies that are
  • 20:52active in the startup process,
  • 20:5490 percent, 90% complete.
  • 20:56You see eight studies, 75% complete,
  • 20:5813 studies and 50% complete for keen study.
  • 21:03Opening a trial is like a scavenger hunt.
  • 21:05There's so many different things to find.
  • 21:07All I ask is everyone who's involved
  • 21:10in trials on this Co-op work together
  • 21:12and through your calls do your yrag.
  • 21:14Let's get these things open 'cause
  • 21:16these trials are for our patients,
  • 21:18but we are working together as a team.
  • 21:21Our regulatory team.
  • 21:22We've got some outside stuff
  • 21:23from your own who are helping us.
  • 21:25Otherwise, CCI team Sarah and CTO team.
  • 21:30Thank you everyone for doing this.
  • 21:32We are getting trials open it it is.
  • 21:37B grade new academic year.
  • 21:39Next slide.
  • 21:42Next slide, please.
  • 21:43Uhm, so these are just two trials
  • 21:45that were active this month is a
  • 21:47third that I've been waiting for a
  • 21:48phone call here on my other phone.
  • 21:50I haven't gotten it yet,
  • 21:51but any minute it's about
  • 21:52to be another cell therapy.
  • 21:56But ah.
  • 22:00Roy, you're breaking up. I don't know if
  • 22:02we're working very hard.
  • 22:05OK. Next slide, please.
  • 22:09And these are just the numbers.
  • 22:11These are, our patients are on trial and
  • 22:13I just show this to show you normally
  • 22:15of the number of patients that we
  • 22:18have on trial and and their accrual.
  • 22:20This is as of last week,
  • 22:22so we had about 50 patients
  • 22:23accrued each year and that's good,
  • 22:25but I'd like to see better,
  • 22:27so I just implore everyone out there.
  • 22:29Whether you're a patient,
  • 22:30whether you're a physician,
  • 22:31whether you're a nurse or
  • 22:33a staff in the clinic,
  • 22:34sink about clinical trials.
  • 22:35Of course we would love
  • 22:37to have more trials open,
  • 22:38but we have plenty of trials open,
  • 22:40so I think is there a trial that will work?
  • 22:42Let's figure out how to make that happen,
  • 22:44and then I think on the last slide.
  • 22:48Uhm, thank you to our staff.
  • 22:50Ummar newsletter will go out
  • 22:52hopefully tomorrow morning and,
  • 22:53uh, Mandy is one of the people
  • 22:55we've spotlighted this month.
  • 22:57Each month we're spotlighting
  • 22:58some of the staff.
  • 22:59It's you that are doing the work,
  • 23:01and I really appreciate everyone
  • 23:03coming together as a team to help
  • 23:05our patients and to help fight
  • 23:07this terrible disease of cancer.
  • 23:09I think that's the last slide.
  • 23:12And I'll just answer questions
  • 23:14as long as it doesn't rain.
  • 23:16Thank
  • 23:16you Roy. Doctor Herbst and thank you
  • 23:19to you and the entire team and I know
  • 23:22that this is reflected in the work that
  • 23:24we do in taking care of her patients.
  • 23:27So again, I think it's nice to
  • 23:29get the updates monthly so we can
  • 23:31then just all sort of work towards
  • 23:33optimizing our clinical trials network.
  • 23:35Alright, I think next is Doctor Burtness
  • 23:38talking about Diane her new role.
  • 23:46Thank you need
  • 23:47a UM, you know, for the opportunity
  • 23:50to to work on on these issues
  • 23:52and for the introduction.
  • 23:54So I wanted to be brief
  • 23:56because we are just starting,
  • 23:58but the first thing that I wanted
  • 24:00to say is I think inclusion is
  • 24:02really a core value for all the
  • 24:05components of the El Cancer Center.
  • 24:08The Yale School of Medicine.
  • 24:09Very explicitly, you know you know,
  • 24:11envisions and inclusive community,
  • 24:13where everyone's voice and contribution
  • 24:16will be valued and respected.
  • 24:17And we create a sense of belonging for all,
  • 24:22and Yale.
  • 24:23New Haven Health sees diversity
  • 24:25and inclusion is important.
  • 24:28Components of organizational values
  • 24:30and is committed to providing
  • 24:32an environment of inclusion.
  • 24:34That's for patients, visitors,
  • 24:36employees, suppliers, the community,
  • 24:38and Yale.
  • 24:39New Haven Health actually has won
  • 24:42many accolades for its support of
  • 24:46LGBT health for fostering a diverse.
  • 24:49Workforce so we start.
  • 24:51I think with a lot of strengths.
  • 24:55Uh, let's see.
  • 24:59Uh.
  • 25:03Don't miss slides. So
  • 25:06what are sort of?
  • 25:08What are some of the challenges going to be?
  • 25:11UM, as we attempt to?
  • 25:14Make sure that we're as inclusive as
  • 25:16possible, that we treat everybody
  • 25:18as equitably as possible and that
  • 25:21we're as diverse as possible and
  • 25:23and so the first thing I think is
  • 25:26understanding where we are.
  • 25:28So I think you know,
  • 25:30don't be surprised if we undertake some
  • 25:33climate surveys or focused interviews
  • 25:35so that we understand where we need to
  • 25:38focus efforts on growing and changing.
  • 25:40And I think one of the things
  • 25:43probably the NCI is.
  • 25:45Can expect from us one of the
  • 25:47things the school may expect from
  • 25:49us or the health system.
  • 25:51If we're asking for resources,
  • 25:52is to be tracking metrics about
  • 25:55how we're doing overtime.
  • 25:56I think Nita started out by by talking
  • 25:59about how important communication is
  • 26:01to building a sense of community,
  • 26:04and I think that that's particularly the
  • 26:07case for members of our Community who
  • 26:09may wonder if they're fully accepted,
  • 26:12or if they, if they're fully incorporated,
  • 26:14so we will be having a part of
  • 26:17direct connect every two weeks.
  • 26:20Is is hopefully going to be
  • 26:22highlighting successes in in diversity,
  • 26:24equity, and inclusion,
  • 26:25but even if they're not.
  • 26:27Some huge steps forward.
  • 26:29We will be trying to highlight resources
  • 26:32and and and work that's ongoing.
  • 26:35Many of us have participated
  • 26:38in implicit bias training,
  • 26:40either online or facilitated in person,
  • 26:43but I think that repeating that
  • 26:47potentially looking at it more extensive.
  • 26:51Trainings and potentially more levels
  • 26:54of the organization may be something
  • 26:57that is worth thinking about.
  • 27:00Certainly at the Med school and Residency
  • 27:03and fellowship level across the country,
  • 27:05there is a lot of work on bringing
  • 27:08the eye issues into the curriculum.
  • 27:12And so we'll be working with the
  • 27:15education leaders on those things.
  • 27:17Uh,
  • 27:17I think one of the things that we
  • 27:19want to see from our leaders is
  • 27:22that they're successful in fostering
  • 27:23an inclusive culture,
  • 27:25and we want to be transparent
  • 27:27when there are some.
  • 27:29Issues of harassment or people
  • 27:31or are having difficulty getting
  • 27:33their their footing because they
  • 27:36don't feel included.
  • 27:37We want to be able to address that.
  • 27:42We, uh, I think, recognize that among our.
  • 27:50Faculty in particular.
  • 27:52There are fewer investigators
  • 27:54who come from groups that are
  • 27:57underrepresented in medicine and science.
  • 27:59Then we would wish,
  • 28:01and so I anticipate in this probably
  • 28:05will will roll onto the person who
  • 28:08takes this role permanently after me,
  • 28:12but that there will be a focus
  • 28:15on recruitment and using a broad
  • 28:18definition of excellence that.
  • 28:21Some permits us to look around the
  • 28:23country at a variety of institutions
  • 28:25to identify people who could
  • 28:27enrich our community,
  • 28:29and then when investigators arrive here,
  • 28:31make sure that there is mentorship
  • 28:33and community that there are internal
  • 28:36funding opportunities that if the
  • 28:38COVID related story has been obviously
  • 28:40very big for women and investigators
  • 28:43of color over the past year,
  • 28:45hopefully that's not going to
  • 28:47be something that's in our
  • 28:49future forever.
  • 28:51Making sure that everyone has equal
  • 28:53access to leadership opportunities and
  • 28:55that we keep the conversation going.
  • 28:57This is work that is going on across
  • 29:01the university and across the school,
  • 29:03and there are many people who are very
  • 29:06passionate about it at many levels
  • 29:08of the organization I just wanted to
  • 29:11highlight three people from Cancer
  • 29:13Center divisions and the Cancer Center
  • 29:16leadership who are particular champions.
  • 29:18So first of all, Harriet Kluger.
  • 29:21Who headed the Committee for the past year,
  • 29:24identified the need for
  • 29:26an associate director.
  • 29:27Really, I think passionately made
  • 29:29the case and has been so effective as
  • 29:32our associate Director of education
  • 29:34training and faculty development and
  • 29:36clearly issues of diversity are very
  • 29:39important for education and faculty
  • 29:41development and we hope to continue
  • 29:44working with her and then two vice
  • 29:47chiefs and hematology and oncology
  • 29:49for dirs irisys Sophie and Pam Kunz.
  • 29:52And then I just come.
  • 29:54There are a lot of resources and they
  • 29:58are all over the health system website.
  • 30:01They are all over the Med school website
  • 30:04and I just wanted to highlight a few
  • 30:08the diversity and inclusion page on
  • 30:11the Yale New Haven Hospital website,
  • 30:13the minority organization for retention
  • 30:15and expansion is a faculty group
  • 30:18which works on welcoming investigators
  • 30:20and faculty from underrepresented.
  • 30:22Groups the Committee on the Status
  • 30:25of Women in Medicine,
  • 30:26which I've been a member of for
  • 30:28about seven years.
  • 30:30Has worked on many issues with regard
  • 30:33to faculty leave compensation,
  • 30:35representation on search committees and
  • 30:38remains. I think a really strong ally.
  • 30:42There is a Yale LGBTQ affinity
  • 30:44group and you can link up with
  • 30:47that through that website.
  • 30:48The Dean has an Advisory Council
  • 30:51on LGBTQ I plus affairs,
  • 30:53and they also maintain an out list
  • 30:55and I many people have already reached
  • 30:58out to just say welcome to me.
  • 31:01In this role.
  • 31:02A few who have reached out because
  • 31:05you have stories that you think
  • 31:08it's important that I hear and I
  • 31:10just wanted to to say bye.
  • 31:13At least my virtual door is always
  • 31:14open and I hope people will reach
  • 31:16out to me and I hope to come back
  • 31:19to you with more stories and in
  • 31:21a couple of months. Thank you.
  • 31:24Thank you Doctor Burtness and I also want
  • 31:26to point out that Kim Slusser is also
  • 31:29leading an effort for the hospital in.
  • 31:31In looking into this from
  • 31:32the health system side,
  • 31:34and she's leading a committee,
  • 31:35so hopefully we can chat and continue
  • 31:37to keep this conversation as a regular
  • 31:39piece both in smile or direct Connect.
  • 31:41And in these sessions Next up is
  • 31:43Doctor Marcus Bosenberg was going
  • 31:45to talk about the new this new as
  • 31:47the novel the director of ICIO.
  • 31:50Thanks so much and and I just wanted
  • 31:53to acknowledge too that we've actually
  • 31:56had a Yale Center for Immuno Oncology
  • 31:59since 2018 and Roy Herbst who was
  • 32:02recently just presented was the
  • 32:04inaugural interim director and I've
  • 32:06functioned in that role since 2019.
  • 32:09And as I think quite a number of
  • 32:11you have noticed that we've had some
  • 32:15very successful symposia annually,
  • 32:17including over 400 attendees.
  • 32:18Last fall there's a seminar series.
  • 32:21That's been part of the Human Translational
  • 32:24Immunology series of one date,
  • 32:25a month up to now,
  • 32:27on Tuesday afternoons at four,
  • 32:29and we've had a number of working groups
  • 32:31over the past year that we will be
  • 32:34continuing and expanding in those roles,
  • 32:36and I just wanted to give a very
  • 32:39brief overview of sort of the vision
  • 32:41and thought for the Center for
  • 32:43Immuno oncology on a longer basis.
  • 32:46And you know,
  • 32:47in short the vision is to be the most
  • 32:50impactful immuno oncology center.
  • 32:51Anywhere, and that's a big and bold goal,
  • 32:54and that will require likely some you know,
  • 32:56raising money through development
  • 32:58and philanthropy which has occurred
  • 32:59also at other centers,
  • 33:01but it builds on the strengths
  • 33:02that we have in our Immunobiology
  • 33:04department here at Yale,
  • 33:06which is viewed as if not the best
  • 33:08one of the very best in the world,
  • 33:11and our strengths and cancer.
  • 33:12So I think it really is possible with
  • 33:15the talent that we have in hand and
  • 33:18I just wanted to give an overview
  • 33:20slide here of some of the core.
  • 33:22Initial areas of interest and core functions.
  • 33:25You know in terms of actual core
  • 33:28like entities you know.
  • 33:29T cell biology is just central
  • 33:31to all of cancer immunology.
  • 33:34There's many aspects of this.
  • 33:36We're also interested in recruiting
  • 33:38additional faculty member or
  • 33:39members in this area.
  • 33:41The tumor microenvironment is a
  • 33:43unique aspect of cancer that doesn't
  • 33:45occur in other areas of immunology,
  • 33:48and those are more on the basic
  • 33:50side but also have some.
  • 33:52Translational and clinical applications.
  • 33:54And then there's some other things
  • 33:56that I'm sure in the future,
  • 33:58either grand rounds or other fora
  • 34:00that I'll explain in greater length,
  • 34:02but looking at ways to personalize
  • 34:04immunotherapy so that we can avoid
  • 34:06immune related adverse events,
  • 34:08which is another area where there has
  • 34:11been some quite a bit of work at Yale,
  • 34:13and I think some strength that we
  • 34:16hope to increase efficacy of these
  • 34:18agents and reduce side effects
  • 34:20from that point of view.
  • 34:22And the bottom 5 boxes.
  • 34:23Here are core or core like functions that
  • 34:26we hope to coordinate through why, CIO?
  • 34:29Some of these exist already.
  • 34:31Some of you are likely aware of the events
  • 34:33cell therapy lab that Diane Krauss leads.
  • 34:36There's a Center for
  • 34:38precision cancer modeling,
  • 34:39wish musami and myself have led that
  • 34:41a number of you have used that.
  • 34:44Does preclinical testing you know,
  • 34:46including of immune oncology
  • 34:47agents and we'd like to coordinate.
  • 34:49And this is to add onto and to help make
  • 34:52even more efficient.
  • 34:54Some existing functions in light
  • 34:56of an immune monitoring core
  • 34:58informatics capabilities at Yale.
  • 34:59But to make it easier for investigators
  • 35:02that are IO oriented to do their
  • 35:05work and also we'd like to add the
  • 35:08ability to collect biospecimens,
  • 35:09for instance bloods,
  • 35:11prior to immune therapy,
  • 35:12and this would add onto existing
  • 35:14efforts at Yale by a number of people,
  • 35:18including in Harriet, Kevin,
  • 35:19Harold and Pat La Russo and others are now.
  • 35:23We're also trying to do this.
  • 35:25In in this space and so how
  • 35:28are we going to do this? Well,
  • 35:30you know there will be some new factor rooms.
  • 35:33There are actually two
  • 35:35slots that are currently.
  • 35:36We had made an announcement last May and
  • 35:39had made some recommendations in terms of
  • 35:42candidates which are still in process.
  • 35:44Now that will likely continue
  • 35:46and we anticipate that this will
  • 35:49continue over the next few years
  • 35:51with a couple hopefully more
  • 35:53slots happening over that time.
  • 35:55And then the other part.
  • 35:56That's really a core aspect of why CIO is
  • 35:59to help yell faculty get into this space,
  • 36:02get funding,
  • 36:02learn about what they can do in this,
  • 36:05and to come to pair them up with
  • 36:07collaborators that are effective in
  • 36:08both their discovery and grant funding.
  • 36:10And you know,
  • 36:11I think that's a real core aspect with all
  • 36:14the talent we have at Yale to help others.
  • 36:17So to add value by,
  • 36:18you know,
  • 36:19enabling the folks that are here at Yale,
  • 36:21and to provide or recruit additional
  • 36:23folks where there are areas.
  • 36:25Or might be a little bit
  • 36:27later in terms of depth,
  • 36:28and I'll I'm actually looking forward to
  • 36:31speaking with a number of you individually.
  • 36:33I'll be reaching out on that basis,
  • 36:35but anytime individuals would like to.
  • 36:38Give input about what they think,
  • 36:40why CIO should be doing.
  • 36:42I'm always list ready to to to talk
  • 36:43or or have a conversation about that
  • 36:45and we will making some announcements
  • 36:47about pilot funding over the next
  • 36:49several months and it will be helpful
  • 36:52to be AY CIO member to do that.
  • 36:54Which basically is submitting a
  • 36:56biosketch and a small paragraph
  • 36:58about why you'd want to be a member.
  • 36:59It's a pretty low bar in terms of
  • 37:02trying to get people to be interested,
  • 37:04but that would be one of the
  • 37:06things that will be doing,
  • 37:08and so I will stop.
  • 37:09Hearing and allow for enough time
  • 37:12for questions,
  • 37:13hopefully.
  • 37:14Thank you so much and thank
  • 37:16you to all our panelists.
  • 37:18I think I'd like to open up
  • 37:20the agenda now for question,
  • 37:22for Q&A and so folks can start
  • 37:24typing it in the chat box.
  • 37:26But while they're doing that,
  • 37:28maybe Monocle asks you a question as we
  • 37:30as as we wait for people to chime in.
  • 37:33I guess you know clearly a lot
  • 37:36of people are curious as to how
  • 37:38implementation will happen and
  • 37:39how do we and I think part of
  • 37:42it reflects our sites, right?
  • 37:44We are big insights.
  • 37:45In scope, and we also then have
  • 37:47so many different disease.
  • 37:49So how do you see that?
  • 37:51Taking across you know from?
  • 37:53In terms of the different phases,
  • 37:55because I think that could,
  • 37:56there's a lot of interest in this
  • 37:58because this effects all of her life.
  • 38:00So maybe if you can spend a couple
  • 38:03minutes on that Monica and I
  • 38:05actually will start off with some.
  • 38:07Each of our work groups has
  • 38:09representation from not only the
  • 38:11network and but the main campus
  • 38:13and the different disease teams,
  • 38:15as well as all the different roles.
  • 38:17So we were purposeful in determining
  • 38:19who was going to participate in each
  • 38:22of the groups so that we had act
  • 38:24adequate representation across all
  • 38:26treatment modalities as well as areas.
  • 38:29And we will do this in phased approach,
  • 38:31so we'll start small with pilots
  • 38:34because it's very easy to.
  • 38:37Modify workflow changes or processes when
  • 38:39you start with a small team and then
  • 38:42as we get better and smoother we will
  • 38:46implement that slowly over different
  • 38:48disease teams as well as locations
  • 38:51and I can tell you that each of the teams.
  • 38:56Everything that one size doesn't fit
  • 38:58all because we know that surgery is
  • 39:00going to be different than radiation
  • 39:02versus Med ONC and we have to be
  • 39:05thoughtful and identifying what are
  • 39:06the key elements within whichever
  • 39:08team it is that we will are.
  • 39:10The are the core elements of that
  • 39:12work and then it may look a little
  • 39:14different within how it is with
  • 39:16rolled out within surgery.
  • 39:18Or you know a specific disease,
  • 39:20team or location.
  • 39:21So we'll start small and
  • 39:22we will continue to add it.
  • 39:24So it's going to take a lot of times.
  • 39:27Come to be able to do this work.
  • 39:31So I see Kim Slusser has also joined
  • 39:33us and maybe Kim would like to add some
  • 39:35other comments or if there is any other
  • 39:37things you'd like to highlight him. Uhm,
  • 39:41no. I I agree with what Monica said.
  • 39:44I think the most important piece and
  • 39:46I know Monica said it a couple of
  • 39:48times is that there is engagement
  • 39:50across all disciplines and all sites.
  • 39:53And we do recognize that the work
  • 39:55may look different within the teams,
  • 39:57but the core principles of what
  • 39:59needs to be done to ensure all
  • 40:01the team members are prepared for
  • 40:03clinic to take care of patients
  • 40:05that adequate coordination of care
  • 40:07happens and that we have efficient
  • 40:09workflows because everybody is really.
  • 40:11Aligned in the work,
  • 40:12I think that's the power of these workgroups.
  • 40:15It's coming together to determine what
  • 40:17those needs are for patients and for
  • 40:19our teams and then creating workflows
  • 40:20to make that happen efficiently.
  • 40:22So, as Monica said,
  • 40:24it's going to take some time
  • 40:26to get across to all areas,
  • 40:27but I think with each implementation as well,
  • 40:30we will learn more and will
  • 40:32keep adapting as we go.
  • 40:33And that's a whole piece
  • 40:35of the process as well,
  • 40:37so it's not kind of this Big Bang.
  • 40:39And then there's a lot of problems.
  • 40:42That we have to go back and solve.
  • 40:43It's that we do this in increments
  • 40:45where we're learning as we go.
  • 40:48And I'm going to just remind folks
  • 40:50to type in their questions and the
  • 40:52panel in the chat so we can see it.
  • 40:55But perhaps the other part.
  • 40:56You know, if if they were starting with the
  • 40:59pile and given the scope came in and Monica,
  • 41:01do you have a timeline in your mind
  • 41:03of when you expect to sort of,
  • 41:05you know, see, you know we're you
  • 41:07know this is 30% of the workforce.
  • 41:09So almost again chart where we can say, OK,
  • 41:12we know we're on the right track and you
  • 41:14know this is like a surgeon talking right?
  • 41:17Everybody knows the surgeons.
  • 41:18Wanna see you know a timeline but
  • 41:20but just sort of bringing it and
  • 41:22again all of this sometimes can be
  • 41:24we can go a little buffer but I think
  • 41:26part of as we start on the journeys.
  • 41:28Also thinking about the finish
  • 41:29goal and what does that look like?
  • 41:31Not that you ever finish,
  • 41:33but I'm going to put you out there a
  • 41:35little bit just to sort of 'cause I
  • 41:37know many people are probably eager to
  • 41:39hear more. Yeah sure.
  • 41:40I think the complaint.
  • 41:41The one thing to think about is
  • 41:43the complexity of each of the work
  • 41:45groups so we know that there's
  • 41:47a lot of effort and focus on.
  • 41:48The checkout process and how can we
  • 41:51make sure that the discussion and
  • 41:53plan with the patient in the during
  • 41:56the clinic translates to someone
  • 41:58doing the next steps of that visit,
  • 42:01whether it's scans, imaging, referrals,
  • 42:03labs you don't or no follow up.
  • 42:06And So what are the and we have
  • 42:09to understand what's out there
  • 42:11for us to use so that we can work
  • 42:14smarter and that we're not putting
  • 42:17burden on one specific person?
  • 42:19So I'm gonna say that the
  • 42:21checkout process is going to be.
  • 42:23A much longer process potentially
  • 42:25than the work that we're going
  • 42:27to do around the pre clinic prep
  • 42:29and the visit criteria so,
  • 42:31so we're already starting the pilot for that,
  • 42:33but I know that the work that's being
  • 42:36done around check out or infusion
  • 42:38may take longer and it's only
  • 42:39going to affect pockets of people.
  • 42:42So I would say that it's months of going,
  • 42:44you know, picking away at this,
  • 42:46but can I tell you that will all
  • 42:49be done by the end of the year?
  • 42:51Or I I can't give it?
  • 42:54Timeline
  • 42:54for no. And then I don't expect
  • 42:55you to, so I I don't like.
  • 42:57I would like to I would
  • 42:58like to say you know what?
  • 43:00By December 31st we're gonna
  • 43:01have all this work done so that
  • 43:03we can move on to the next part,
  • 43:04but that's not the reality.
  • 43:05So but I can tell you that.
  • 43:08You know we've had, UM,
  • 43:10the group of people that are participating
  • 43:12are so engaged they attend our meetings,
  • 43:14there's homework with each of our groups.
  • 43:17They come back with the information
  • 43:19because we asked them to go back
  • 43:21to different teams and stakeholders
  • 43:23to ask for feedback on things
  • 43:25that we're working on.
  • 43:26And all that is done.
  • 43:28So it is.
  • 43:29It is really I'm speaking on the
  • 43:31work of many that are really spending
  • 43:34a lot of time on this so that it
  • 43:37is really valuable in the end.
  • 43:39We don't want you know.
  • 43:40The worst,
  • 43:40the last thing we want is to spend
  • 43:42a tremendous amount of time and
  • 43:44then not see impact at the end, so.
  • 43:47And I would just say that I think as we
  • 43:49launch and we mentioned this last month
  • 43:52that Kevin Billingsley and I are getting
  • 43:55ready to launch the Clinical Council.
  • 43:56I think that will be one venue that the
  • 43:59ambulatory transformation team will be coming
  • 44:01to on a regular basis to give updates.
  • 44:04And then these town halls to continue
  • 44:06to come back and give updates because
  • 44:08I think it's important for the teams
  • 44:10for all the teams to know where
  • 44:13we're at and the progress.
  • 44:14And as Monica said, all of these work.
  • 44:17Close will have metrics attached to them,
  • 44:19and that's critical to to know
  • 44:21how much we are improving.
  • 44:23You know our operations and our care
  • 44:25delivery for our patients so and and and
  • 44:27the environment in which our teams work.
  • 44:30So I think that that's just critical
  • 44:32to have those venues and I would
  • 44:34say if there are areas that want
  • 44:36to hear in more detail about the
  • 44:38specific initiatives you know,
  • 44:40please reach out and we
  • 44:41can make sure that we have.
  • 44:43There are lots of the leaders
  • 44:45have been going on the road.
  • 44:47So to make sure that everyone knows the
  • 44:50work that's being done and that can and
  • 44:53that they can contribute to that work.
  • 44:55So don't be shy and just let us know.
  • 45:00Thank you in Monica and Monica, Renee.
  • 45:02If I miss any questions
  • 45:04please keep me honest.
  • 45:05I think the other part Barbara.
  • 45:07I know you mentioned in your chat
  • 45:09in your conversation that many
  • 45:10have already reached out to you,
  • 45:12but if people want to reach out to you,
  • 45:14I presume it be nice to highlight your email.
  • 45:17I presume most people know how to
  • 45:19get in touch with you, but if not,
  • 45:21I'll ask Renee to highlight that information.
  • 45:23I was thinking about that that we
  • 45:25probably want to make sure people
  • 45:27know how to reach you easily and I
  • 45:29don't know if.
  • 45:30If if the slides get shared on,
  • 45:33people can find it, but it was.
  • 45:35It was the last resource on the
  • 45:37slide and it's Barbara. Ducker will
  • 45:38share so people can. I
  • 45:40know you're just both.
  • 45:41You and Marcus are just beginning
  • 45:43the journey, so I don't want
  • 45:44to put you on the spot, right?
  • 45:46I'd like to come back with one
  • 45:48question and I know many people I've
  • 45:50been listening to various groups,
  • 45:52the Clinical Trials Office are
  • 45:53physicians who are on the front
  • 45:55lines as well as the leaders,
  • 45:57and I guess as I'm learning about the
  • 45:59clinical trials, I'm stuck by how many.
  • 46:01Details are there.
  • 46:02A lot of people have expressed
  • 46:04their desire to help.
  • 46:05How can they help us?
  • 46:07I mean, I think you mentioned some of this.
  • 46:10You know, answer those you know.
  • 46:11Get those things.
  • 46:12Perhaps you can speak a little bit on that.
  • 46:15How can folks help?
  • 46:16'cause I know there's a big
  • 46:18desire to make these things you
  • 46:20know start activate on time.
  • 46:22But how can folks help you
  • 46:24and look CTO office? Thanks.
  • 46:25That's a very good point.
  • 46:27There's so many processes involved
  • 46:29in getting trials activated,
  • 46:30and it often involves.
  • 46:31Input from the dark until investigators,
  • 46:34what's? What's it?
  • 46:35What's a billable item for
  • 46:37a clinical versus research?
  • 46:38Sometimes you need a form style 1572.
  • 46:41There have been people who have had
  • 46:44expired trainings, so when you get
  • 46:46an email from the CTO for that,
  • 46:49please try to do it right away.
  • 46:52Work with your administrative support.
  • 46:54We really need that.
  • 46:56Things like filing the actual paperwork.
  • 46:58I'd rather have a CTO team do you.
  • 47:01You know,
  • 47:02I know people have offered to do that too,
  • 47:04but I think we should have, you know,
  • 47:07the regulatory work is so precise,
  • 47:08will have the team do that,
  • 47:10but we do have so many things that go
  • 47:12back and forth and everything takes time.
  • 47:15You know, it's it's like any other project.
  • 47:17Project management is so important
  • 47:18we're making progress.
  • 47:19We have.
  • 47:20We're hiring more regulatory
  • 47:21staff of our own.
  • 47:22We already have some amazing people you know,
  • 47:24like basically.
  • 47:25And then we're also bringing
  • 47:26in extra help from your on.
  • 47:28But we need the investigator that
  • 47:30the dark teams, uh, the nurses.
  • 47:31That the staff to all they'll be engaged,
  • 47:34and it also doesn't hurt to push you.
  • 47:36I don't mind people pushing.
  • 47:37I push you have your trial.
  • 47:39It's your research, you know,
  • 47:40make it happen and again,
  • 47:42you know with limits.
  • 47:43But we want to try to get
  • 47:45these things going in,
  • 47:46and I'm certainly I'm an investigator
  • 47:48myself so I know what it means and I care.
  • 47:51And I'm certainly around to help as well.
  • 47:54Thank you doctor.
  • 47:55So I mean it's positive engagement and
  • 47:57we want though all the oars rowing in
  • 47:59the same direction than any comments
  • 48:00from you on the broader things.
  • 48:02I think we had a lot of good news.
  • 48:05Anything else you want to point out?
  • 48:07I know you're here and joining us on
  • 48:09the panelist here. No,
  • 48:10I think we had a good summary today.
  • 48:14The director search is ongoing.
  • 48:15They understand that they have
  • 48:17completed the first round of
  • 48:19interviews for a new director.
  • 48:21And we make a recommendation,
  • 48:22or at least a list of suggested names
  • 48:24to the Dean by the end of the month.
  • 48:26And that in the meantime,
  • 48:28we are proceeding with our renewal for
  • 48:30the major Cancer Center support grant.
  • 48:32Will get were actually just this week
  • 48:34we started giving instructions to
  • 48:35write to start writing the new grant.
  • 48:38So let let going on.
  • 48:39Yeah and lot going on
  • 48:41and thank you and I think
  • 48:43from what I've heard.
  • 48:44Although I'm not on the search committee,
  • 48:46but I've heard lots of great candidates.
  • 48:48So I think the search committee is
  • 48:50really excited about our next director.
  • 48:52Alright, if there's no more questions.
  • 48:54I know it's a long holiday and I want.
  • 48:57Sort of safe.
  • 48:58We're done 10 minutes or 9 minutes early.
  • 49:00I don't think anyone's going to be upset.
  • 49:03It's again, I do encourage the folks if
  • 49:05they want to ask questions. You know,
  • 49:07there's only a certain number of ways,
  • 49:09so typing the questions
  • 49:10either directly to me.
  • 49:11If you don't feel comfortable sharing it
  • 49:13with everybody is also a way to do this.
  • 49:15I know all of you want to ask questions,
  • 49:18so I know you're not shy,
  • 49:20but I do encourage you to ask if
  • 49:22we don't know what's on your mind,
  • 49:24we can't answer that question, so again,
  • 49:26hopefully will build up that interaction.
  • 49:27And those muscles.
  • 49:28But thank you to all our panelists.
  • 49:31You're very good.
  • 49:31You kept it on schedule and we're even
  • 49:34finished a few minutes early, Renee,
  • 49:36just I think you wanted me to remind them no,
  • 49:39no town hall in August.
  • 49:40And if they have agenda items in mind,
  • 49:43I think I'm going to get this right.
  • 49:45Cancer answers at yale.edu.
  • 49:47If you have questions and things you want,
  • 49:49see here.
  • 49:50Again, if you send us those things,
  • 49:52we can bring them up.
  • 49:53But if if I if we don't hear from you,
  • 49:56then I will kind of.
  • 49:58Shooting in the dark,
  • 49:59but I will try to bring all the news.
  • 50:02Good bad positive news things we
  • 50:04want to talk about as a community.
  • 50:06So thank you all.
  • 50:07Please enjoy the long weekend.
  • 50:08If you do have some time,
  • 50:10I hope everyone gets some time off this
  • 50:12weekend to enjoy and hopefully it'll
  • 50:14cool down a bit and everyone can enjoy.
  • 50:16So thank you everybody.
  • 50:17Thank you to all our panelists.
  • 50:19Doctor Hurst.
  • 50:20Thankfully we heard you and it
  • 50:22didn't rain so it but the clouds
  • 50:24back behind you look really dark
  • 50:25so I would get inside alright.
  • 50:27Take care everybody bye bye.